A Global Neuronopathic Gaucher Disease Registry (GARDIAN): A Patient-Led Initiative
Preprint
- 5 April 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder. GD types 2 and 3 are known as neuronopathic Gaucher disease (nGD) because they have brain involvement that progresses over time. Implementing a systematic approach to the collection of real-world clinical and patient-relevant outcomes data in nGD presents an opportunity to fill critical knowledge gaps and ultimately help healthcare providers in the management of this patient population. This paper summarizes the development of a patient-initiated Gaucher Registry for Development Innovation and Analysis of Neuronopathic Disease (GARDIAN). Methods The International Gaucher Alliance led the GARDIAN planning, including governance, scope, stakeholder involvement, platform, and reporting. Registry element input was determined in a series of meetings with clinical experts, patients, and caregivers, who identified key clinical variables and the draft content of nGD patient-reported outcomes (PRO) and observer-reported outcomes (ObsRO) focusing on symptoms, patient physical and emotional functioning. These were then tested in cognitive interviews with patients with nGD (> 12 years of age) and caregivers. Results Core registry data elements (n = 138) were identified by seven global clinical experts from Egypt, Germany, Israel, Japan, United Kingdom (UK), and United State (US) and reviewed via online Delphi method by 14 additional clinicians with experience of nGD from six countries and three pharmaceutical representatives. The elements were consistent with those identified via interviews with 10 patients/caregivers with nGD from Japan, Sweden, UK, and US. Key domains identified were demographics, diagnostic information, health status, clinical symptomatology, laboratory testing, treatment, healthcare resource utilization, aids/home improvements, and patient/caregiver burden and quality of life, specifically physical functioning, self-care, daily and social activities, emotional impacts, support services, and caregiver-specific impacts. Nine caregivers and six patients from the US, UK, China, Mexico, Egypt, and Japan participated in the cognitive interviews that informed revisions to ensure that all items are understandable and interpreted as intended. Conclusions The comprehensive set of clinical and patient relevant outcomes data, developed collaboratively among all stakeholders, to be reported using GARDIAN will bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome SurveyBlood Cells, Molecules, and Diseases, 2018
- Patient-Centered Drug Approval: The Role of Patient Advocacy in the Drug Approval ProcessJournal of Managed Care & Specialty Pharmacy, 2017
- Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshopResearch Involvement and Engagement, 2017
- GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in researchBMJ, 2017
- Integrating patient voices into health information for self-care and patient-clinician partnerships: Veterans Affairs design recommendations for patient-generated data applicationsJournal of the American Medical Informatics Association, 2016
- Impaired gait kinematics in type 1 Gaucher’s DiseaseJournal of Parkinson’s Disease, 2016
- The history and accomplishments of the ICGG Gaucher registryAmerican Journal of Hematology, 2015
- Four‐year follow‐up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring toolJournal of Inherited Metabolic Disease, 2011
- The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)Journal of Inherited Metabolic Disease, 2010
- Management of neuronopathic Gaucher disease: A European consensusJournal of Inherited Metabolic Disease, 2001